Exit
In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing of at least 100% on this post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements. 

There is no fee to participate in this activity.

Question Title

* 1. Where are you in your career?

Question Title

* 2. What is your community of practice?

Question Title

* 3. In the analysis of the True North open-label extension, the findings indicated that approximately half the patients who failed to achieve a clinical response after 10 weeks of ozanimod induction treatment benefitted from which of the following:

Question Title

* 4. Which drug combinations were given in the Phase 2a VEGA proof-of-concept study to show the potential of dual inhibition of interleukin-23 and tumor necrosis factor α to more effectively induce clinical response and remission in patients with moderately severe UC?

Question Title

* 5. Which of the following patient reported outcome (PRO) questionnaires assesses patient fatigue using a 13-item tool and 5-point scale, where a higher score indicates a better patient outcome?

Question Title

* 6. In the U-ACHIEVE Maintenance study, looking at patients with ulcerative colitis who responded to induction therapy with upadacitinib at 8 weeks, which treatment group led to greater clinical remission per adapted Mayo score at week 52 compared to placebo?

Question Title

* 7. Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity). 

Completing the fields below does not immediately qualify you for a CME certificate. Only after completing the post-survey & evaluation form will a certificate be issued.

*Please note that we will not forward or sell your contact information.*

( Privacy & Cookie Notice

T